Capecitabine

證據等級: L5

預測適應症: 10 個

Capecitabine: From Colorectal Cancer to Gastric Tubular Adenocarcinoma

One-Sentence Summary

Capecitabine is an oral fluoropyrimidine prodrug originally approved for colorectal cancer and breast cancer, selectively converted to active 5-fluorouracil (5-FU) within tumor tissue by thymidine phosphorylase (TP). The TxGNN model predicts efficacy across 10 gastric cancer subtypes (scores 99.89–99.94%); among these, Gastric Tubular Adenocarcinoma (TxGNN Rank #3) carries the strongest clinical foundation, supported by 20 publications including multiple completed Phase 3 RCTs that directly establish CAPOX (capecitabine + oxaliplatin) as adjuvant standard-of-care in gastric cancer—though the drug is currently not registered in Canada.

Quick Overview

Item	Content
Original Indication	Colorectal cancer; breast cancer
Predicted New Indication	Gastric Tubular Adenocarcinoma (strongest evidence; TxGNN overall Rank #3)
TxGNN Prediction Score	99.94%
Evidence Level	L1
Canada Market Status	Not Marketed
Number of DINs	0
Recommended Decision	Proceed with Guardrails

Multi-Indication Overview

This evidence pack covers 10 gastric cancer subtypes predicted by TxGNN. Evidence strength and recommendations vary substantially across subtypes:

Rank	Disease	TxGNN Score	Evidence Level	Recommendation
1	Gastric Adenocarcinoma and Proximal Polyposis of the Stomach (GAPPS)	99.94%	L5	Hold
2	Microinvasive Gastric Cancer	99.94%	L5	Hold
3	Gastric Tubular Adenocarcinoma ⭐	99.94%	L1	Proceed with Guardrails
4	Signet Ring Cell Gastric Adenocarcinoma	99.94%	L2	Research Question
5	Gastric Cardia Adenocarcinoma	99.91%	L1	Proceed with Guardrails
6	Carcinoma of Stomach, Salivary Gland Type	99.91%	L3	Research Question
7	Gastric Pylorus Carcinoma	99.91%	L4	Research Question
8	Gastric Body Carcinoma	99.90%	L1	Proceed with Guardrails
9	Epstein-Barr Virus-Associated Gastric Carcinoma	99.90%	L4	Research Question
10	Malignant Gastric Granular Cell Tumor	99.89%	L5	Hold

The remainder of this report focuses on Gastric Tubular Adenocarcinoma (⭐), the subtype with the strongest clinical evidence base. Gastric Cardia Adenocarcinoma and Gastric Body Carcinoma also reach L1 and are reflected in the clinical trials and literature sections below.

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the database. Based on established pharmacology, capecitabine is an orally administered prodrug that undergoes a three-step enzymatic conversion to 5-fluorouracil (5-FU), with the final activation step catalyzed by thymidine phosphorylase (TP) — an enzyme substantially overexpressed in tumor tissue relative to normal gastrointestinal mucosa. Gastric tubular adenocarcinoma is the predominant histological subtype of Lauren intestinal-type gastric cancer, and intestinal-type tumors are known to exhibit particularly high TP activity, making them an ideal substrate for capecitabine’s selective tumor-site activation mechanism.

Colorectal cancer and gastric tubular adenocarcinoma share overlapping molecular characteristics: both arise from gastrointestinal epithelium, both show chromosomal instability (CIN) as a dominant genomic pathway, and both demonstrate robust sensitivity to fluoropyrimidine-based chemotherapy. This mechanistic and biological continuity explains why the clinical evidence for capecitabine in gastric cancer is exceptionally strong — the drug’s development trajectory followed the same TP-mediated activation logic from colorectal to gastric settings. The TxGNN model appears to be capturing this genuine pharmacological signal rather than generating a spurious high-score prediction.

The evolution of capecitabine from a single adjuvant agent (established by CLASSIC Phase 3 RCT) to a perioperative backbone (confirmed by RESOLVE) and then to the chemotherapy partner of choice for immunotherapy combinations (confirmed by KEYNOTE-859, CheckMate-649, RATIONALE-305, ORIENT-16, and GLOW) demonstrates its versatile and deeply validated position across all treatment settings of gastric adenocarcinoma. The uniformly high TxGNN scores (99.89–99.94%) across all 10 gastric subtypes therefore reflect genuine cross-subtype biological signal, though evidence quality diverges sharply between common histological subtypes (tubular, cardia, body) and rare variants (GAPPS, granular cell tumor, salivary gland type).

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00374036	Phase 3	Completed	416	REAL2 trial: 2×2 factorial design comparing capecitabine vs. 5-FU and oxaliplatin vs. cisplatin in advanced gastric/GEJ adenocarcinoma. Capecitabine arm confirmed non-inferior to 5-FU — highest-level direct evidence establishing capecitabine as an oral first-line backbone.
NCT00040859	Phase 2	Completed	48	CAPOX (capecitabine + oxaliplatin) in metastatic esophageal, gastroesophageal junction, and gastric cardia adenocarcinoma. Direct subtype-specific evaluation in the cardia; demonstrates activity and tolerability of the CAPOX combination.
NCT00938470	Phase 2	Completed	73	Randomized Phase 2 of extended neoadjuvant therapy for locally advanced adenocarcinoma of the esophagus, GEJ, and gastric cardia; capecitabine-containing arm included, supporting preoperative use.
NCT06238752	Phase 2	Completed	33	Apatinib + tislelizumab + XELOX (capecitabine + oxaliplatin) as first-line treatment for HER2-negative advanced G/GEJ cancer, including signet ring cell carcinoma; provides Phase 2 safety data for CAPECITABINE in combination with anti-angiogenic and immunotherapy.
NCT01295086	Phase N/A (dose-finding)	Completed	27	TEX (docetaxel + oxaliplatin + capecitabine) + trastuzumab in HER2-positive advanced gastroesophageal cancer including cardia; confirms capecitabine tolerability within a triplet cytotoxic combination.
NCT00414271	Phase 2	Completed	18	Neoadjuvant chemotherapy in locally advanced gastric cancer; investigates thymidylate synthase (TS) expression by IHC as a predictive biomarker for 5-FU/capecitabine response — directly mechanistically relevant.
NCT07091227	Phase 2	Not Yet Recruiting	66	AK112 (PD-1/VEGF bispecific antibody) + chemotherapy as neoadjuvant treatment specifically designed for signet ring cell–containing gastric/GEJ adenocarcinoma; prospective subtype-specific evidence generation planned.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
22226517	2012	RCT Phase 3	Lancet	CLASSIC trial: CAPOX adjuvant chemotherapy vs. observation after D2 gastrectomy in Stage II–IIIB gastric cancer (n=1,035). Landmark trial directly establishing capecitabine + oxaliplatin as post-surgical standard-of-care; disease-free survival benefit confirmed.
34252374	2021	RCT Phase 3	Lancet Oncology	RESOLVE trial: Perioperative SOX vs. postoperative CAPOX after D2 gastrectomy for locally advanced gastric/GEJ cancer; confirms CAPOX as standard adjuvant regimen with comparable efficacy to SOX in the perioperative setting.
39952264	2025	RCT Phase 3	Lancet Oncology	RESOLVE final report: Updated overall survival analysis from the RESOLVE trial; long-term confirmation of CAPOX benefit in locally advanced gastric cancer after D2 gastrectomy.
37524953	2023	RCT Phase 3	Nature Medicine	GLOW trial: Zolbetuximab + CAPOX (capecitabine + oxaliplatin) in CLDN18.2-positive HER2-negative advanced gastric/GEJ adenocarcinoma; capecitabine-containing regimen achieves statistically significant survival benefit in molecularly selected patients.
34102137	2021	RCT Phase 3	Lancet	CheckMate 649: Nivolumab + chemotherapy (capecitabine/oxaliplatin-based) vs. chemotherapy alone for advanced HER2-negative gastric/GEJ/esophageal adenocarcinoma; large Phase 3 trial confirming capecitabine as the chemotherapy backbone in the immunotherapy era.
38806195	2024	RCT Phase 3	BMJ	RATIONALE-305: Tislelizumab + chemotherapy (including capecitabine) vs. placebo + chemotherapy as first-line treatment for advanced gastric/GEJ adenocarcinoma; positive Phase 3 result in a broad population.
37875143	2023	RCT Phase 3	Lancet Oncology	KEYNOTE-859: Pembrolizumab + chemotherapy (capecitabine-containing) vs. placebo + chemotherapy for HER2-negative advanced gastric/GEJ adenocarcinoma; overall survival benefit confirmed.
38051328	2023	RCT Phase 3	JAMA	ORIENT-16: Sintilimab (anti-PD-1) + chemotherapy (capecitabine-containing) vs. chemotherapy alone for unresectable gastric/GEJ cancer; independent Phase 3 replication of capecitabine-immunotherapy combination benefit.
30982686	2019	RCT Phase 3	Lancet	FLOT4 trial: FLOT vs. ECF/ECX perioperative chemotherapy for locally advanced resectable gastric/GEJ adenocarcinoma; ECX (epirubicin + cisplatin + capecitabine) arm represents the established capecitabine-containing perioperative regimen as active comparator.
16303863	2006	Phase 2 Trial	Annals of Oncology	CAPOX in metastatic adenocarcinoma of the esophagus, GEJ, and gastric cardia (NCCTG Phase 2, n=48). Direct early evidence of capecitabine + oxaliplatin activity specifically in the cardia subtype; confirmed tolerability and preliminary efficacy.

Cytotoxicity

Item	Content
Cytotoxicity Classification	Conventional cytotoxic (Fluoropyrimidine class; orally administered prodrug of 5-fluorouracil)
Myelosuppression Risk	Moderate (neutropenia and thrombocytopenia reported; generally less myelosuppressive than continuous-infusion IV 5-FU)
Emetogenicity Classification	Low to moderate
Monitoring Items	CBC with differential (baseline and each cycle), renal function (creatinine clearance essential for dose adjustment), liver function tests
Handling Protection	Must follow cytotoxic drug handling regulations; oral tablet dispensing requires appropriate institutional controls

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails (applicable to L1-evidence subtypes: Gastric Tubular Adenocarcinoma, Gastric Cardia Adenocarcinoma, Gastric Body Carcinoma)

Rationale: The CLASSIC (PMID 22226517) and RESOLVE (PMID 34252374) Phase 3 RCTs directly establish CAPOX as adjuvant standard-of-care after D2 gastrectomy; REAL2 (NCT00374036, n=416) confirms capecitabine non-inferiority to 5-FU across advanced gastric cancer; and at least five additional major Phase 3 trials (KEYNOTE-859, CheckMate-649, RATIONALE-305, ORIENT-16, GLOW) have successfully incorporated capecitabine as the chemotherapy backbone in immunotherapy combinations. This constitutes an overwhelming base of Level 1 evidence for the three L1-designated subtypes. TxGNN’s uniformly high prediction scores (99.89–99.94%) reflect genuine mechanistic and clinical signal rather than model artifacts.

To proceed, the following is needed:

Verify Health Canada registration status: capecitabine may already hold DINs for colorectal or breast cancer indications — a search of the Health Canada Drug Product Database is required to confirm current approval scope and whether gastric cancer is included or accessible via off-label use
Obtain the Canadian product monograph to establish the full safety profile for prescribing
Complete MOA data retrieval from DrugBank (DrugBank ID: DB01101) to support formal pharmacological justification documents
Establish a safety monitoring protocol including CBC monitoring, creatinine clearance assessment for dose adjustment, and hand-foot syndrome surveillance
For Ranks 1–2 (GAPPS, microinvasive gastric cancer) and Rank 10 (malignant gastric granular cell tumor): maintain Hold — these require dedicated evidence generation before any clinical application can be considered
For Rank 4 (signet ring cell), Rank 6 (salivary gland type), Rank 7 (pylorus), and Rank 9 (EBV-associated): treat as Research Questions — subtype-specific biomarker-stratified prospective studies are needed before routine clinical implementation
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.